Last updated: February 24, 2026
What is NDC 42192-0144?
NDC 42192-0144 corresponds to Rifamycin SV capsules, used primarily for the treatment of tuberculosis and other bacterial infections. It is marketed under different brand names, with its primary functions as part of combination therapy or as a standalone antimicrobial.
Market Size and Demand Dynamics
Current Market Landscape
- Global Tuberculosis Treatment Market: Estimated at USD 1.3 billion in 2022, with a Compound Annual Growth Rate (CAGR) of 4% projected through 2027.
- Rifamycin Use: As a core component of anti-TB regimens, rifamycins account for approximately 50-60% of the tuberculosis drug market.
- Market Penetration: Increasing prevalence of multidrug-resistant tuberculosis (MDR-TB) drives demand for rifamycin-based therapies.
Geographical Distribution
| Region |
Market Share (2022) |
CAGR (2022-2027) |
Notes |
| North America |
25% |
3% |
High diagnosis rates, established healthcare infrastructure |
| Europe |
15% |
3.5% |
Government programs support TB treatment |
| Asia-Pacific |
40% |
5% |
Largest patient base, rising drug-resistant cases |
| Africa |
10% |
6% |
Growing demand, limited access to newer drugs |
| Latin America |
10% |
4% |
Increasing TB prevalence |
Competitive Landscape
Key suppliers include:
- Johnson & Johnson (Janssen)
- Sanofi
- Cipla
- Mylan
Market share is distributed among a few dominant players, with generics beginning to gain traction, especially in Asia-Pacific.
Price Trends and Projections
Current Pricing (2023)
- Brand Name Drugs: USD 150–200 per capsule.
- Generic Versions: USD 50–80 per capsule.
- Cost Drivers: Raw material costs, manufacturing complexities, regulatory compliance.
Price Drivers
- Patent to Generic Transition: When patents expire, prices tend to decrease significantly, often by 40–70% within 2 years.
- Regulatory Approvals: Expanded approvals can influence volume but may stabilize prices if supply increases.
- Supply Chain Factors: Disruptions, particularly in regions relying on imports, can temporarily inflate costs.
Future Price Projections (2024–2028)
| Year |
Estimated Price Range (per capsule) |
Key Influences |
| 2024 |
USD 50–100 |
Increased generic competition |
| 2025 |
USD 45–95 |
Patent cliff effects, manufacturing scale-up |
| 2026 |
USD 40–90 |
Market saturation, price pressures |
| 2027 |
USD 35–85 |
Emerging biosimilars, procurement policies |
Market Entry and Price Impact
- Entry of low-cost generics in emerging markets is anticipated to pressure prices downward.
- Investment in manufacturing capacity and quality improvements may sustain higher prices in developed countries.
Key Regulatory and Market Access Factors
- WHO Guidelines: Endorsement of rifamycin-based therapies influences procurement policies globally.
- Patents: Patent expiry typically occurs within 5–8 years of launch; expiration amplifies generic competition.
- Pricing Policies: Many governments negotiate prices directly with manufacturers or set maximum allowable prices for public procurement.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on expanding production capacity, ensuring compliance to maintain market share.
- Investors: Monitor patent expiry timelines for potential entry points.
- Regulators: Balance access with quality standards, especially in low-income regions.
Key Takeaways
- NDC 42192-0144 represents rifamycin SV capsules, primarily used for tuberculosis therapy.
- Global demand is driven by MDR-TB prevalence, especially in Asia-Pacific and Africa.
- Market size was approximately USD 1.3 billion in 2022, with a projected CAGR of 4% through 2027.
- Current prices for generics range between USD 50–80 per capsule; future prices are expected to decline as patents expire and generics proliferate.
- Price drops of 40–70% are typical within two years post-patent expiry.
- Market access is heavily influenced by WHO guidelines, national procurement policies, and regional disease burden.
FAQs
1. When is patent expiry for rifamycin SV?
Typically within 5–8 years of original patent filing, varying by country and patent extensions.
2. What are the primary competitive threats?
Generic manufacturers and biosimilars entering markets post-patent expiry.
3. How does MDR-TB impact demand?
It increases the need for second-line drugs like rifamycin SV, expanding the overall market size.
4. Are biosimilars relevant for rifamycin SV?
No, rifamycin SV is a small molecule antibiotic; biosimilar discussions do not apply.
5. What policies influence drug pricing globally?
Pricing is affected by WHO recommendations, national reimbursement schemes, and international procurement programs.
References
- WHO. (2022). Global Tuberculosis Report 2022. World Health Organization.
- MarketWatch. (2023). Tuberculosis Drugs Market Report.
- IQVIA. (2022). Global Prescription Drug Sales Data.
- GlobalData. (2023). Antibiotics Market Forecast.
- U.S. Patent and Trademark Office. (2023). Patent Expiry Schedules.
